Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
A medication helped preserve muscle mass in people taking weight-loss drugs, suggesting a way to maintain strength during intentional weight reduction.
This randomized double-blind placebo-controlled phase 2 trial examined Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. This study establishes proof of concept for GDF8 inhibition by trevogrumab alone as a generally well tolerated strategy to preserve lean mass during GLP-1 receptor agonist-induced weight loss.
What the study was
- Study design
- Randomized double-blind placebo-controlled phase 2 trial
- Sample size
- 605
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Lancet (London, England)
Why it surfaced
Retained after review of PubMed metadata and abstract because its randomized double-blind placebo-controlled phase 2 trial directly informs cardiovascular-metabolic; scoring was capped conservatively for design and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.